BNTX BioNTech SE - Fundamental Analysis
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
Powered by advanced machine learning algorithms
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Rule-based valuation fallback.
- P/B of 1.3 keeps valuation grounded.
Rule-based growth outlook.
- Revenue growth running at 22.0%.
Historical performance + price trend: Shares moved +14.1% over 5Y and -0.5% over 1Y.
- Insufficient data for clear positives.
- ROE only -3.0%.
- Thin profit margins.
Balance sheet & liquidity snapshot.
- D/E ratio of 0.01 keeps leverage manageable.
- Current ratio 7.1 supports liquidity.
Dividend policy fallback.
- Insufficient data for clear positives.
- No regular dividend payments.
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for BNTX and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
BNTX
BioNTech SE
Primary
|
+14.1% | -37.0% | -0.5% | +11.1% | -1.2% | -0.1% |
|
DXCM
DexCom, Inc.
Peer
|
-31.7% | -50.1% | -22.2% | -32.1% | -11.2% | +5.6% |
|
HUM
Humana Inc.
Peer
|
-42.2% | -52.3% | -15.1% | +0.4% | -9.6% | -5.9% |
|
BMRN
BioMarin Pharmaceutical Inc.
Peer
|
-29.0% | -36.5% | -16.6% | -7.7% | +3.1% | +6.3% |
|
EW
Edwards Lifesciences Corporation
Peer
|
+5.0% | +13.6% | +30.4% | +10.6% | +18.3% | +3.5% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
BNTX
BioNTech SE
|
NEUTRAL | $24.79B | - | -3.0% | -18.1% | $103.09 | |
|
DXCM
DexCom, Inc.
|
BULLISH | $23.29B | 32.26 | 30.6% | 16.0% | $58.06 | |
|
HUM
Humana Inc.
|
NEUTRAL | $28.52B | 22.18 | 7.2% | 1.0% | $237.12 | |
|
BMRN
BioMarin Pharmaceutical Inc.
|
NEUTRAL | $10.51B | 20.35 | 9.1% | 16.8% | $54.73 | |
|
EW
Edwards Lifesciences Corporation
|
NEUTRAL | $50.08B | 37.85 | 13.5% | 23.2% | $86.3 |
Wall Street Analysts
Professional analyst ratings and price targets